Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 1/20 | 0.45 |
| ▸ | HTR1A | P08908 | 6/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | CCR3 | P51677 | 1/20 | 0.40 |
| ▸ | CCR5 | P51681 | 1/20 | 0.40 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6409656 | 0.90 | CCR5 (0.47) | HSD11B1LMNANPSR1CCR3CCR5 | |
| Hydrochloric Acid SCHEMBL6415467 | 0.89 | CCR5 (0.46) | HSD11B1LMNANPSR1CCR3CCR5 | |
| SCHEMBL5410651 | 0.88 | LMNA (0.43) | HSD11B1LMNANPSR1CCR3CCR5 | |
| SCHEMBL6415563 | 0.87 | HSD11B1 (0.45) | HSD11B1LMNANPSR1CCR3CCR5 | |
| SCHEMBL6411982 | 0.87 | HSD11B1 (0.43) | IGF1RHSD11B1LMNANPSR1CCR3 | |
| Hydrochloric Acid SCHEMBL6409417 | 0.86 | HSD11B1 (0.42) | IGF1RHSD11B1LMNANPSR1CCR3 | |
| Hydrochloric Acid SCHEMBL6416497 | 0.86 | HSD11B1 (0.42) | IGF1RHSD11B1LMNANPSR1CCR3 | |
| Hydrochloric Acid SCHEMBL6409958 | 0.86 | HSD11B1 (0.44) | HSD11B1LMNANPSR1CCR3CCR5 | |
| SCHEMBL6409590 | 0.86 | LMNA (0.42) | HSD11B1LMNANPSR1CCR3CCR5 | |
| SCHEMBL6411476 | 0.85 | OPRL1 (0.51) | HSD11B1CCR3CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075326-A1 | Spiro compounds and methods for the modulation of chemokine receptor activity | VIROCHEM PHARMA INC (CA) | 2005-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075326-A1 | Spiro compounds and methods for the modulation of chemokine receptor activity | CXCR1, CXCR4, CXCR2 | IGF1R 2464/4885HTR1A 1039/4885HSD11B1 120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.